Replies to post #120297 on Biotech Values

[DewDiligence]

Ablynx…this is already a very crowded space and I don't see why nanobodies would be advantageous in this particular application.

They would presumably have an advantage in production cost relative to mAbs (Humria, Remicade) or fusion proteins (Enbrel), but this in itself probably isn’t a sufficient impetus for commercialization.

[DewDiligence]

…[TNF-a] is already a very crowded space and I don't see why nanobodies would be advantageous in this particular application.

Neither did PFE, evidently.